From Design to Delivery: A Translational Framework for Non-Viral Gene Editing
Biomarker discovery is essential to advancing precision medicine, yet researchers face common challenges: complex assays that generate massive datasets, imaging workflows that are difficult to scale and connecting results into actionable insights remains a struggle. These barriers slow discovery, limit reproducibility and make it harder to translate findings into clinical impact.
In this webinar, discover how Leica Microsystems and Molecular Devices, life sciences companies of Danaher, address these challenges through integrated, AI-powered solutions. Learn how advanced imaging and analytics platforms accelerate phenotypic screening, reveal spatial and morphological context and help you move from data to discovery with greater speed, confidence and translational relevance.
Key takeaways:
- Gain spatial insights and cellular context using Aivia AI Image Analysis Software from Leica Microsystems
- Reduce the time and complexity of phenotypic screening with IN Carta Image Analysis Software from Molecular Devices
Speakers
Ashley Jacobi, Director, Applications & Market Development, Integrated DNA Technologies (IDT)
Headshot & Bio (50-80 words): Ashley received her Molecular Genetics & Biochemistry degree from Cornell College in 2006 and has spent the last 20 years in several roles within the Research & Product Development teams at IDT. She has conducted research in RNAi and antisense oligo technologies, and more recently focused on studying CRISPR gene editing. Ashley is also a certified practitioner in Customer Insight and leads external scientific collaborations at IDT.
IDT custom guide RNAs and CRISPR off-target solutions: early research to therapeutic development
Max Sellman, Senior Product Manager, Aldevron
Headshot & Bio (50-80 words): Max Sellman is Senior Product Manager, Gene Editing, at Aldevron focusing on gene editing protein products and custom services since 2017. He partners closely with research and translational-phase clients to ensure they have the right tools and insights to drive successful therapeutic development. Max holds a bachelor’s degree from the University of Wisconsin in Genetics and Life Sciences Communication.
Enabling production of next-generation genetic medicines through comprehensive CRISPR manufacturing solutions
gatedform
gatedform
546005641
non-viral-gene-editing-wbn
add
Other
promotion
https://lifesciences.danaher.com/
https://help.salesforce.com/s/articleView?id=sf.mc_es_demanager.htm